{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:25:39Z","timestamp":1788265539455,"version":"build-2803163510"},"reference-count":54,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Issues Mol. Biol.","CIMB"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) affects one-quarter of the global population. The disease may progress from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma. Unfortunately, lifestyle interventions and pharmacotherapies provide limited benefits to NAFLD patients. This systematic review which was conducted according to PRISMA 2020 guidelines, study selection, and data extraction, evaluated preclinical studies published between 1 January 2021 and 4 April 2026 that investigated liposome-based nanocarriers for NAFLD\/NASH. Out of 477 records identified, 19 studies met the eligibility criteria and were included in the review. The included studies demonstrated that liposomal formulations prepared using thin-film hydration exhibited characteristics such as particle sizes of 80\u2013160 nm, low polydispersity, zeta potentials of \u221255 to +35 mV (depending on surface modification), encapsulation efficiencies exceeding 75%, and sustained biphasic release profiles. Mechanistically, these nanocarriers targeted pathways by suppressing de novo lipogenesis through inhibition of FASN and SREBP-1c, enhancement of fatty acid oxidation through activation of AMPK signaling, mitigation of oxidative stress through Nrf2-mediated antioxidant responses, suppression of inflammation via NF-\u03baB and TLR4 signaling, and attenuation of hepatic fibrosis via inhibition of the TGF-\u03b2\/Smad pathway. Selected formulations also achieved adipose tissue targeting, thereby highlighting their potential to modulate liver\u2013adipose tissue metabolic crosstalk. Despite these promising preclinical findings, clinical translation remains limited by methodological heterogeneity, inconsistent stability assessment, insufficient safety data, absence of clinical trials, biological barriers such as rapid mononuclear phagocyte system clearance, protein corona formation, and restricted penetration through the fibrotic extracellular matrix. Moreover, there are challenges in large-scale manufacturing and batch-to-batch reproducibility. Thus, rigorous toxicological evaluation and well-designed clinical trials are essential for facilitating the clinical translation of liposomal nanomedicines for treatment of liver diseases.<\/jats:p>","DOI":"10.3390\/cimb48090883","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:33:32Z","timestamp":1788262412000},"page":"883","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liposomal Nanocarriers in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Formulation Design, Targeting Strategies, and Therapeutic Outcomes"],"prefix":"10.3390","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1378-7140","authenticated-orcid":false,"given":"Sahar M.","family":"AlMotwaa","sequence":"first","affiliation":[{"name":"Applied College, Shaqra University, Shaqra 11961, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-4832","authenticated-orcid":false,"given":"Waad A.","family":"Al-Otaibi","sequence":"additional","affiliation":[{"name":"Department of Chemistry, College of Science and Humanities, Shaqra University, Shaqra 11961, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41575-023-00880-2","article-title":"Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases","volume":"21","author":"Stefan","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41575-023-00832-w","article-title":"Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis","volume":"20","author":"Sharma","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"goae029","DOI":"10.1093\/gastro\/goae029","article-title":"Advancements in pharmacological treatment of NAFLD\/MASLD: A focus on metabolic and liver-targeted interventions","volume":"12","author":"Ciardullo","year":"2024","journal-title":"Gastroenterol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Abou Assi, R., Abdulbaqi, I.M., and Yee, C.S. (2021). The evaluation of drug delivery nanocarrier development and pharmacological briefing for metabolic-associated fatty liver disease (MAFLD): An update. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030215"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17016","DOI":"10.1021\/acsnano.1c02158","article-title":"Design of hepatic targeted drug delivery systems for natural products: Insights into nomenclature revision of nonalcoholic fatty liver disease","volume":"15","author":"Tang","year":"2021","journal-title":"Acs Nano"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1039\/D2BM01252A","article-title":"Pharmaceutical liposomal delivery-specific considerations of innovation and challenges","volume":"11","author":"Peng","year":"2022","journal-title":"Biomater. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Haghighi, E., Abolmaali, S.S., Dehshahri, A., Shaegh, S.A.M., Azarpira, N., and Tamaddon, A.M. (2024). Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: A quality-by-design approach. J. Nanobiotechnol., 22.","DOI":"10.1186\/s12951-024-02972-w"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1039\/D4TB00186A","article-title":"Looking back, moving forward: Protein corona of lipid nanoparticles","volume":"12","author":"Gao","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"ref_13","first-page":"428","article-title":"Liposomes for drug delivery: Review of vesicular composition, factors affecting drug release and drug loading in liposomes","volume":"51","author":"Pande","year":"2023","journal-title":"Nanomed. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1620\/tjem.2023.J050","article-title":"Liposomal Silybin Improves Glucose and Lipid Metabolisms in Type 2 Diabetes Mellitus Complicated with Non-Alcoholic Fatty Liver Disease via AMPK\/TGF-\u03b21\/Smad Signaling","volume":"261","author":"Cai","year":"2023","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1039\/D2BM02161G","article-title":"ROS-scavenging nanomedicine for \u201cmultiple crosstalk\u201d modulation in non-alcoholic fatty liver disease","volume":"11","author":"Xin","year":"2023","journal-title":"Biomater. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1021\/acsptsci.3c00210","article-title":"Liposome-based silibinin for mitigating nonalcoholic fatty liver disease: Dual effects via parenteral and intestinal routes","volume":"6","author":"Yan","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12951-021-00979-1","article-title":"Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice","volume":"19","author":"Chen","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"126564","DOI":"10.1016\/j.ijbiomac.2023.126564","article-title":"Enhancing stability of liposomes using high molecular weight chitosan to promote antioxidative stress effects and lipid-lowering activity of encapsulated lutein in vivo and in vitro","volume":"253","author":"Zhang","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Farooq, A., Iqbal, A., Rana, N.F., Fatima, M., Maryam, T., Batool, F., Rehman, Z., Menaa, F., Azhar, S., and Nawaz, A. (2022). A Novel Sprague-Dawley Rat Model Presents Improved NASH\/NAFLD Symptoms with PEG Coated Vitexin Liposomes. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063131"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1007\/s11357-024-01068-5","article-title":"Eliminating senescent cells by white adipose tissue-targeted senotherapy alleviates age-related hepatic steatosis through decreasing lipolysis","volume":"46","author":"Tang","year":"2024","journal-title":"Geroscience"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hou, Y., Gao, X., Gong, J., Dong, X., Hao, Y., Zhai, Z., Zhang, H., Zhang, M., Liu, R., and Wang, R. (2025). Targeted Sodium Acetate Liposomes for Hepatocytes and Kupffer Cells: An Oral Dual-Targeted Therapeutic Approach for Non-Alcoholic Fatty Liver Disease Alleviation. Nutrients, 17.","DOI":"10.3390\/nu17050930"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.arcmed.2023.04.001","article-title":"Glucagon-modified Liposomes Delivering Thyroid Hormone for Anti-obesity Therapy","volume":"54","author":"Liu","year":"2023","journal-title":"Arch. Med. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jpp\/rgad031","article-title":"Chrysin and its nanoliposome ameliorated non-alcoholic steatohepatitis via inhibiting TLR4 signalling pathway","volume":"75","author":"Liu","year":"2023","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jfutfo.2024.04.003","article-title":"Synergistic effect on nonalcoholic fatty liver disease by aptamer functionalized liposome loading allicin","volume":"6","author":"Li","year":"2026","journal-title":"J. Future Foods"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"126657","DOI":"10.1016\/j.ijpharm.2026.126657","article-title":"Balancing immune evasion and hepatocyte delivery: A hybrid liposomal platform for enhanced nanotherapy in non-alcoholic fatty liver disease","volume":"692","author":"Tang","year":"2026","journal-title":"Int. J. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7838","DOI":"10.1038\/s41467-022-35470-4","article-title":"Adipose-targeted triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects","volume":"13","author":"Chen","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e18529","DOI":"10.1111\/jcmm.18529","article-title":"The effects of simvastatin-loaded nanoliposomes on human multilineage liver fibrosis microtissue","volume":"28","author":"Parsa","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Su, M., Cao, D., Wang, Z., Duan, Y., and Huang, Y. (2021). Fatty Acid Synthase Inhibitor Platensimycin Intervenes the Development of Nonalcoholic Fatty Liver Disease in a Mouse Model. Biomedicines, 10.","DOI":"10.3390\/biomedicines10010005"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"147670","DOI":"10.1016\/j.gene.2023.147670","article-title":"Enhancement of biochemical and genomic pathways through lycopene-loaded nano-liposomes: Alleviating insulin resistance, hepatic steatosis, and autophagy in obese rats with non-alcoholic fatty liver disease: Involvement of SMO, GLI-1, and PTCH-1 genes","volume":"883","author":"Salem","year":"2023","journal-title":"Gene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"19786","DOI":"10.1039\/D5RA02554K","article-title":"Galactose receptor-mediated hepatic targeting system: Engineering of quinary cationic liposomes for resveratrol delivery against hepatic steatosis","volume":"15","author":"Liang","year":"2025","journal-title":"RSC Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1007\/s12010-024-05089-w","article-title":"Spirulina platensis Peptide-Loaded Nanoliposomes Alleviate Hepatic Lipid Accumulation in Male Wistar Rats by Influencing Redox Homeostasis and Lipid Metabolism via the AMPK Signaling Pathway","volume":"197","author":"Karimzadeh","year":"2025","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"130595","DOI":"10.1016\/j.ijbiomac.2024.130595","article-title":"Construction of nanoparticles from blueberry anthocyanins-lecithin\/gum Arabic improves lipid droplet accumulation and gut microbiota disturbance in HFD-induced obese mice","volume":"264","author":"Cheng","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_34","unstructured":"Morad, H. (2026). Fundamentals and Therapeutic Applications of Liposomes, Academic Press."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s43246-026-01073-5","article-title":"Engineering the biophysical properties of lipid nanostructures for drug delivery","volume":"7","author":"Menge","year":"2026","journal-title":"Commun. Mater."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12645-019-0055-y","article-title":"Nanomedicine review: Clinical developments in liposomal applications","volume":"10","year":"2019","journal-title":"Cancer Nanotechnol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19207","DOI":"10.1039\/D4NR02480J","article-title":"Nanomaterial journey in the gut: From intestinal mucosal interaction to systemic transport","volume":"16","author":"Qiao","year":"2024","journal-title":"Nanoscale"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12951-025-03479-8","article-title":"Advanced oral drug delivery systems for gastrointestinal targeted delivery: The design principles and foundations","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1021\/acs.molpharmaceut.0c00194","article-title":"Platensimycin-encapsulated liposomes or micelles as biosafe nanoantibiotics exhibited strong antibacterial activities against methicillin-resistant Staphylococcus aureus infection in mice","volume":"17","author":"Wang","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_40","first-page":"100430","article-title":"Revolutionary hyaluronic acid-modified edge-activated spanlastics as a novel approach to boost Hepatoprotective activity of Curcumin: Optimization, biochemical analysis and in-vivo assessment","volume":"10","author":"Ahmed","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"13122","DOI":"10.1021\/acsami.4c03800","article-title":"Chitosan coating as a strategy to increase postemergent herbicidal efficiency and alter the interaction of nanoatrazine with Bidens pilosa plants","volume":"17","author":"Sousa","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"125881","DOI":"10.1016\/j.ijpharm.2025.125881","article-title":"Effect of positive charges on liposome stability, uptake efficacy and impact on cells","volume":"681","author":"Zhao","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Agrawal, S.S., Baliga, V., and Londhe, V.Y. (2024). Liposomal formulations: A recent update. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17010036"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s44395-025-00021-5","article-title":"Techniques in the characterization of lipid-based nanotherapeutics: State of the art, challenges, and future direction","volume":"1","author":"Pattnaik","year":"2025","journal-title":"Discov. Pharm. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"118722","DOI":"10.1016\/j.ijpharm.2019.118722","article-title":"Freeze-drying cycle optimization for the rapid preservation of proteinloaded liposomal formulations","volume":"573","author":"Hussain","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Pasarin, D., Ghizdareanu, A.-I., Enascuta, C.E., Matei, C.B., Bilbie, C., Paraschiv-Palada, L., and Veres, P.-A. (2023). Coating materials to increase the stability of liposomes. Polymers, 15.","DOI":"10.3390\/polym15030782"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Sato, H., Yamada, K., Miyake, M., and Onoue, S. (2023). Recent advancements in the development of nanocarriers for mucosal drug delivery systems to control oral absorption. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15122708"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ly, P.-D., Ly, K.-N., Phan, H.-L., Nguyen, H.H.T., Duong, V.-A., and Nguyen, H.V. (2024). Recent advances in surface decoration of nanoparticles in drug delivery. Front. Nanotechnol., 6.","DOI":"10.3389\/fnano.2024.1456939"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Jiang, C., Sun, H., Jiang, Z., Tian, W., Cang, S., and Yu, J. (2024). Targeting the CD47\/SIRP pathway in malignancies: Recent progress, difficulties and future perspectives. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1378647"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/08820139.2024.2415409","article-title":"The physiological and therapeutic role of CD47 in macrophage function and cancer","volume":"54","author":"Bess","year":"2025","journal-title":"Immunol. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage","volume":"172","author":"Lila","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"125753","DOI":"10.1016\/j.ijpharm.2025.125753","article-title":"Biomimetic approaches against accelerated blood clearance (ABC) phenomenon of nanoparticulate drug delivery systems","volume":"680","author":"Jan","year":"2025","journal-title":"Int. J. Pharm."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/9\/883\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:10:39Z","timestamp":1788264639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/9\/883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cimb48090883"],"URL":"https:\/\/doi.org\/10.3390\/cimb48090883","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]}}}